KMT2A (MLL) fusions and KMT2A-PTD (partial tandem duplication) are important biomarkers in
myeloid malignancies.
This biomarker has garnered much interest, as ongoing clinical trial research has shown that acute leukemias harboring KMT2A rearrangements may be susceptible to small molecule inhibitors that target the KMT2A-menin protein complex1.
While KMT2A rearmaments are traditionally detected by RT-qPCR (quantitative real-time PCR), a recent study presented at the American Association of Cancer Research Annual Meeting 2024 has demonstrated the use of next generation sequencing (NGS) with Oncomine Myeloid Assay GX v2 at the Genexus System to detect KMT2A fusions in myeloid malignancy samples and KMT2A-PTDs in both healthy donors and myeloid malignancy samples.
